Article
NEJM has published the results of an observational trial wherein tofacitinib given to patients hospitalized with Covid-19 pneumonia, was shown to significantly lower risk of death or respiratory failure.
All News
Article
It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.
Article
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Article
Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
Article
Lancet Respiratory Medicine has reported the results of the COLCORONA trial, showing that in patients with PCR-confirmed COVID-19 infection, colchicine led to a significantly lower rate of death or hospital admission from COVID.
Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Article
One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.
Article
The NEJM has published the results of a French multicenter study showing that prosthetic joint infections can be successfully managed with 6 weeks of antibiotic therapy; this was noninferior and had better outcomes compared to 12 weeks of antibiotic therapy.
Article
JAMA Internal Medicine report an analysis of recent and composite trial data suggesting that tocilizumab (TCZ) therapy in COVID-19–associated pneumonia patients with high CRP levels is likely to be effective.
Article
Analysis of data from the COVID-19 Global Rheumatology Alliance shows that rheumatic diseases infected with COVID-19 had a greater risk of death with age, comorbidities, high disease activity and few specific therapies.
Article
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com
Article
Patients with psoriasis or psoriatic arthritis who were being treated with ustekinumab (Stelara) had lower rates of serious hospitalized infections than patients receiving other biologics or small molecule therapies, a study utilizing data from two commercial claims databases found.
Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com - a website for rheumatologists, by rheumatologists.
We love Rheumatology!
Dr. John Cush
Tweet
#EULAR2021 and EULAR IQ
Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg
Aurelie Najm
Tweet
COSMOS study: Guselkumab RCT in PsA pts TNFi-resistants (1 or 2) 44.4% of GUS vs 19.8% of PBO pts achieved ACR20 at w24 (p<0.001) and GUS > PBO for most secondary endpoints. Tolerance: 18% vs. 20% infections/SI.
#OP0230 @Rheumnow #EULAR2021 @DrLauraCoates https://t.co/fFle2OR8KM
Aurelie Najm
Tweet
Serious infections and BioDMARDs: what is the confounding factor?
BSRBR-RA: 33,916 RA treated w/ BioDMARDs with 62,532 years of follow-up, 2036 SI. HR of SI no longer different among BioDMARDs when adjusted for the line of therapy! #OP0241@Rheumnow #EULAR2021 https://t.co/UG9WrXP7RD
Aurelie Najm
Tweet
Patients with RA > 70yo and risk of severe infection: which therapeutic strategy is the safest?
#EULAR2021 @Rheumnow #OP0116
Meral K. El Ramahi, MD
Tweet
➡️5 cases of single-dermatome Herpes Zoster in 4 patients treated w/ UPA 15 mg QD for active AS in SELECT-AXIS 1
⭐️Do not forgot to vaccinate patients with 1st dose of Shingrix prior to starting a JAK-i. 2nd dose can be given after start of therapy
OP0144 #EULAR2021 @RheumNow
Janet Pope
Tweet
You put a pt on a #Jaki What is most likely infection that will occur? #EULAR2021 @RheumNow @eular_org
Dr. John Cush
Tweet
Italian study of 1216 rheumatic pts on DMARDs, Biologics underwent HBV testing. They found HBV in 15.7% (chronic infection: 0.4%, resolved infection: 12.6%, anti-HBc positivity alone: 2.6%). HBV reactivation occurred in 6.2%. Only 1 acute hepatitis https://t.co/WofN4rqq6p
